Please provide your email address to receive an email when new articles are posted on . Acute disease exacerbations fell to 66% with treatment — a 56% reduction — compared with placebo. Congestion, ...

ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical ...

An exhalation delivery system that releases fluticasone into the nasal cavity for the treatment of chronic rhinosinusitis enhanced sleep quality and alleviated sinonasal symptoms in patients with ...

Please provide your email address to receive an email when new articles are posted on . The Exhalation Delivery System reaches inflamed areas of the nasal cavity and sinuses that other sprays miss.

PHILADELPHIA – An exhalation delivery system that uses a patient’s own breath to carry the anti-inflammatory compound fluticasone (EDS-FLU) directly to the sinuses reduced chronic sinus infection ...